News & Updates
Filter by Specialty:
Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer
The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.
Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer
07 Nov 2025
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.
Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy
06 Nov 2025
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).